Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cell Metab ; 28(1): 118-129.e5, 2018 Jul 03.
Article in English | MEDLINE | ID: mdl-29805100

ABSTRACT

We investigated relationships among immune, metabolic, and sleep abnormalities in mice with non-metastatic mammary cancer. Tumor-bearing mice displayed interleukin-6 (IL-6)-mediated peripheral inflammation, coincident with altered hepatic glucose processing and sleep. Tumor-bearing mice were hyperphagic, had reduced serum leptin concentrations, and enhanced sensitivity to exogenous ghrelin. We tested whether these phenotypes were driven by inflammation using neutralizing monoclonal antibodies against IL-6; despite the reduction in IL-6 signaling, metabolic and sleep abnormalities persisted. We next investigated neural populations coupling metabolism and sleep, and observed altered activity within lateral-hypothalamic hypocretin/orexin (HO) neurons. We used a dual HO-receptor antagonist to test whether increased HO signaling was causing metabolic abnormalities. This approach rescued metabolic abnormalities and enhanced sleep quality in tumor-bearing mice. Peripheral sympathetic denervation prevented tumor-induced increases in serum glucose. Our results link metabolic and sleep abnormalities via the HO system, and provide evidence that central neuromodulators contribute to tumor-induced changes in metabolism.


Subject(s)
Breast Neoplasms/complications , Breast Neoplasms/metabolism , Interleukin-6/immunology , Metabolic Diseases/etiology , Neurons/metabolism , Orexins/physiology , Sleep Wake Disorders/etiology , Animals , Breast Neoplasms/drug therapy , Cell Line, Tumor , Female , Ghrelin/metabolism , Glucose/metabolism , Hyperphagia , Leptin/blood , Mammary Neoplasms, Experimental , Mice , Mice, Inbred BALB C , Orexin Receptor Antagonists/therapeutic use , Sleep/drug effects
2.
Sci Rep ; 7(1): 8152, 2017 08 15.
Article in English | MEDLINE | ID: mdl-28811490

ABSTRACT

Breast cancer survivors are more likely to develop mood disorders and cognitive deficits than women in the general population. Previous studies suggest that peripheral tumors elicit central pro-inflammatory cytokine production, in turn leading to depression and cognitive deficits. In the current study, two cohorts of female Balb/C mice received bilateral orthotopic injections of syngeneic 67NR, 4T07, or 4T1cells (1 × 105 cells per injection) to induce mammary tumors. Approximately three weeks later, learned fear (via fear conditioning) or depressive-like behavior (via tail suspension and forced swim test) was assessed. Proinflammatory cytokine levels were increased in the serum (IL-1ß, TNFα, IFNγ) and livers (IL-1ß, IL-6, TNFα) of mice with 4T07 or 4T1 tumors compared to 67NR tumors and the vehicle control. IL-1ß was increased in both the hippocampus and cortex of mice injected with 4T07 or 4T1 cell lines relative to the other treatment groups. However, mammary tumors had no effect on hippocampal doublecortin + and did not alter depressive-like behavior or learned fear. These data demonstrate that similarly sized tumors can produce differential immune responses and that tumor-induced central pro-inflammatory cytokine production can exist in the absence of depressive-like behavior or cognitive deficits.


Subject(s)
Cytokines/genetics , Cytokines/metabolism , Gene Expression Regulation, Neoplastic , Inflammation Mediators/metabolism , Mammary Neoplasms, Animal/genetics , Mammary Neoplasms, Animal/metabolism , Animals , Behavior, Animal , Body Mass Index , Cell Line, Tumor , Female , Mice , Mice, Inbred BALB C , Motor Activity , Spleen/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...